Beckman Coulter, Inc. Commercializes First Automated Inhibin A Assay

FULLERTON, Calif., April 16 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC - News), the leading manufacturer of diagnostics instruments in the U.S., has introduced Access® Inhibin A -- the first automated assay for the quantitative determination of dimeric inhibin A levels in human serum and plasma. Inhibin A is used as an aid in the diagnosis and monitoring of various reproductive hormonal disorders. Through the acquisition of Diagnostic System Laboratories, Inc. (DSL), Beckman Coulter has an exclusive license to manufacture and market the assay.